Home / Beam Therapeutics Inc. (BEAM)
Stock Analysis
Beam Therapeutics Inc. (BEAM)
31.12 +7.20%
Updated: 2026-06-16 10:37 UTC
Technology-style analysis layer: price structure, momentum, key levels and business quality in one view.
WOI Investment Thesis
Constructive
Momentum: Neutral
Range: 78% of 52W range
Bull35.41
Base35.41
Bear29.69
Key Levels
Resistance35.41
Support29.69
Invalidationlosing 29.43 would weaken the current structure.
Upside Target—
Price Chart
BEAM · Interactive chart workspace
Open Full Workspace
Analyst Narrative
Beam Therapeutics Inc. (BEAM) closed at 31.12 (+7.20%). Trend remains constructive above MA50 and MA200. Momentum: +11.42%; 52W position: 77% of range; and Volatility: ATR14 7.41%. RSI(14) stands around 53.8, which keeps the momentum picture broadly balanced. RSI has been trending higher in recent sessions, indicating improving momentum conditions. MACD is positioned under the signal line, suggesting momentum recovery has not fully developed yet. The MACD histogram remains negative, suggesting momentum is still on the softer side.
🔺
Setup: Pattern Triangle compression remains the main pattern under review.
🎯
Key levels: Key levels The nearest decision zone is framed by support at 29.69 and resistance at 35.41.
⚠️
Risk: A move through resistance would improve the short-term technical tone, while a loss of support would weaken the current structure.
Technical Setup
🔺 Technical Setup
Pattern
Triangle Compression / SYM / DOWN
State
Forming
Breakout Watch
Downtrend line not broken yet · score 0
Watch Level
33.85
Compression
64%
RSI(14)
53.8
🎯 Decision Map
The nearest decision zone is framed by support around 29.43 and resistance near 31.43. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Business Lens
💼 Fundamentals Snapshot
Source: sec
💼 Business Lens
QUALITY VIEW
Financial quality snapshot
Financial context is mixed
📈 Growth: Strong 💰 Profit: Negative 💵 Cash: Mixed 🛡 Balance: Manageable
• Quarterly revenue growth remains strong and still points upward.
• Quarterly profitability remains weak, with net margin below zero.
💵 Revenue
31.74M
📈 Net Income
-94.32M
🧮 EPS (Basic)
-0.91
🏢 Company
Beam Therapeutics Inc.
🏷 Sector
Healthcare
🧩 Industry
Biotech
Compare with related stocks
Same sector and industry ideas for deeper research
Amgen (AMGN) technical analysisAxsome Therapeutics (AXSM) technical analysisCRISPR Therapeutics AG (CRSP) technical analysisAmicus Therapeutics (FOLD) technical analysisImmunitybio (IBRX) technical analysisImmunome (IMNM) technical analysisAbbVie (ABBV) technical analysis
Note: This is an algorithmic technical snapshot, not financial advice.